Amgen gains rights to Servier's heart drugs ivabradine and S38844

10 July 2013

USA-based Amgen (Nasdaq: AMGN), the world’s largest independent biotech firm, has entered a new collaboration with privately-held French drugmaker Laboratoire Servier leveraging each company's commitment to cardiovascular disease.

Under the terms of the accord, financial terms of which were not disclosed, Amgen has obtained commercial rights in the USA to Servier's novel oral drug ivabradine, approved in the European Union as Procoralan, for chronic heart failure and stable angina in patients with elevated heart rates. Amgen has also received an exclusive option to develop and commercialize Servier's investigational molecule, S38844, for cardiovascular diseases in the USA. Currently, S38844 is in Phase II studies for the treatment of heart failure.

…while Servier acquires omecamtiv mecarbil for Europe

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK